CTIS2024-513446-12-00招募中1 期
An open, randomized-controlled, multi-center phase-II clinical trial of individualized immunosuppression with intravenously administered donor modified immune cells (MIC) compared to standard-of-care in living donor kidney transplantation - TOL-2
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 126
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Donors: 1. Age =18 years and able to consent, Patients: 7. Negative CDC crossmatch with the donor, Patients: 8. Negative PCR test result for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Screening, Patients: 9. Patient's living donor gave written consent for trial participation, Patients: 10. Ability to understand the nature and scope of the clinical trial, Patients: 11. Written informed consent given prior to any trial-related procedures, Patients: 12. Female patients of childbearing potential must: a. have a negative pregnancy test (blood) at Screening. b. either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, 2 highly effective measures of contraception control (failure rate less than 1% per year when used consistently and correctly) without interruption, during the trial participation. Patients who discontinue mycophenolic acid derivate during the trial participation can switch to 1 highly effective contraceptive method 6 weeks after the end of mycophenolic acid derivative treatment. Reliable methods for this trial are: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence or vasectomized sexual partner. Abstinence from heterosexual contact is only accepted as true abstinence: when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal] is not an acceptable method of contraception.) Postmenopausal (no menses for at least 1 year without alternative medical cause) or surgically sterile female patients (tubal ligation, hysterectomy or bilateral oophorectomy) may be enrolled. c. agree to abstain from breast feeding during the trial participation., Patients: 13. Male patients must practice true abstinence or agree to use a condom during sexual contact with a pregnant woman or a woman of childbearing potential during the trial participation and for at least 90 days after the end of trial participationmycophenolic acid derivative treatment, even if he has undergone a successful vasectomy., Donors: 2. Ability to understand the nature and scope of the clinical trial, Donors: 3. Written consent form given prior to any trial-related procedures (including PBMC donation), Patients: 1. Patient with CKD in stage 5 (e.g., estimated glomerular filtration rate [GFR] <15mL/min and/or on renal replacement therapy), who are in preparation for kidney transplantation from a live donor, Patients: 2. Age =18 years, <75 years, Patients: 3. ABO-blood group identical or compatible with donor, Patients: 4. First kidney transplantation, Patients: 5. Complement dependent cytotoxicity (CDC)-panel reactive antibodies <20%, Patients: 6. No detection of a donor-specific HLA-antibody in the Luminex-Assay (cutoff: mean fluorescence intensity [MFI] =1,000)
排除标准
- •Donors: 1. Pregnant or breastfeeding, Donors: 18. Unexplained night sweats, unexplained fever, unexplained weight loss, prolonged unexplained cough or diarrhea, unexplained skin lesions, lymph gland swelling or thrush, Donors: 19. Dura mater and/or cornea grafts, allogeneic organ transplants, xenotransplants, pituitary hormones of human origin received, Donors: 2. Participation in an interventional clinical trial within 30 days prior to Screening or in observation period of a competing study, Donors: 20. Stay of longer than 6 months in the United Kingdom between 1980 and 1996 and/or an operation and/or blood transfusion in the United Kingdom after 01-Jan 1980, Donors: 21. Operations or other invasive interventions (e.g., endoscopies, biopsies, catheter applications, acupunctures [except acupuncture with sterile and/or disposable needles]) within 4 months prior to Screening, Donors: 22. Any invasive exposure to blood (i.e., allogeneic blood components or plasma derivatives) or blood-contaminated injection needles or instruments, tattoos or piercings within 4 months prior to Screening, Donors: 23. Positive PCR test result for SARS-CoV-2 at Screening, Donors: 24. Hemoglobin <8.0 g/dL, thrombocytes <80,000/µL and/or leukocytes <3,000/µL, Donors: 25. Known history of hypersensitivity to components used in the leukapheresis setting (i.e., components of the anticoagulant acid citrate dextrose solution), Donors: 26. Any finding or medical condition prohibiting the inclusion in the trial according to the judgment of the responsible leukapheresis physician, Donors: 10. Active bacterial, mycotic or viral infection, Patients: 1. Preexisting severe psychiatric disorder, Patients: 2. Heart insufficiency of grade NYHA III or IV, Patients: 3. Severe liver disease (aspartate aminotransferase or alanine aminotransferase or gamma glutamyl transpeptidase =3 x ULN), Donors: 3. Severe psychiatric disease, Patients: 4. Active infection of HIV, HBV, HCV, EBV, or syphilis, Patients: 5. Active bacterial, mycotic, or viral infection, Patients: 6. Negative serological test result for antibodies specific for Epstein-Barr virus (EBV) antigens (Note: EBV negative patients can be included if the donor is confirmed EBV negative), Patients: 7. Malignant disease within 2 years prior to Screening, except basal cell carcinomas of the skin and in situ carcinomas, Patients: 8. Immunosuppressive therapy (e.g., for the treatment of an auto-immune disease) within 6 months prior Screening, Patients: 9. Preexisting vasculitis or collagenosis, Donors: 11. Known malaria infection; known infection of tuberculosis, Q fever, Salmonella typhi and paratyphi, or osteomyelitis (if not medically documented to have been cured for 2 years); known toxoplasmosis (except if symptom free for 6 months); after completion of treatment for rheumatic fever (except if treatment was completed for 2 years), Patients: 10. Known presence of irregular antibodies in Coombs test, Patients: 11. Vaccination within 4 weeks prior to Screening, Patients: 12. Spleen removed, Patients: 13. Known or suspected abuse of alcohol, drugs, or medicinal products, Donors: 4. Severe cardiovascular diseases (i.e., heart insufficiency of grade NYHA III or IV), Patients: 14. Pregnant or breastfeeding, Patients: 16. Known history of hypersensitivity to the cellular components or to any other constituent/excipient in the pharmaceutical formulation of MIC (e.g., components of the SSP+ buffer as electrolytes (sodium chloride, pot
研究者
相似试验
进行中（未招募）
1 期
A non blinded phase-II study with 3 randomized patient groups of individualized suppression of the patient's immune system with donor modified immune cells (MIC) compared to standard-of-care in kidney transplantation from living donorsiving donor kidney transplantationMedDRA version: 20.0Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-000561-33-DETolerogenixX GmbH126
进行中（未招募）
1 期
Clinical trial with GRASPA, Red Blood cells encapsulating L-Asparaginase, in patients affected by Acute Myeloid leukemiaEUCTR2012-002026-78-ESERYTECH Pharma123
进行中（未招募）
1 期
Clinical trial with GRASPA, Red Blood cells encapsulating L-Asparaginase, in patients affected by Acute Myeloid leukemiaAcute Myeloid LeukaemiaMedDRA version: 18.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2012-002026-78-DEERYTECH Pharma123
进行中（未招募）
1 期
Clinical trial with GRASPA, Red Blood cells encapsulating L-Asparaginase, in patients affected by Acute Myeloid leukemiaAcute Myeloid LeukaemiaMedDRA version: 14.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2012-002026-78-FIERYTECH Pharma123
进行中（未招募）
1 期
Clinical trial with GRASPA, Red Blood cells encapsulating L-Asparaginase, in patients affected by Acute Myeloid leukemiaEUCTR2012-002026-78-ITERYTECH Pharma123